ESPR FY 2017 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

FY 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

-$258,000

Operating Income

-$169M

Net Income

-$167M

EPS (Diluted)

$-6.98

Cash Flow

Operating Cash Flow

-$131M

Free Cash Flow

-$131M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$278M

Total Liabilities

$33M

Stockholders' Equity

$245M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$258,000	-$252,000	-2.4%
Operating Income	-$169M	-$76M	-121.9%
Net Income	-$167M	-$75M	-122.7%